Robert Howes
Profile
Robert Howes worked as Director of Research & Development at Horizon Discovery Ltd.
and as Principal at Ligand UK Ltd., Stanford University, and the University of Cambridge.
He holds a doctorate degree from the University of Cambridge.
Former positions of Robert Howes
Companies | Position | End |
---|---|---|
VERNALIS | Corporate Officer/Principal | - |
Stanford University | Corporate Officer/Principal | - |
University of Cambridge | Corporate Officer/Principal | - |
Horizon Discovery Ltd.
Horizon Discovery Ltd. Miscellaneous Commercial ServicesCommercial Services Horizon Discovery Ltd. develops and supplying patient-relevant drug discovery and diagnostic research tools. The frm also supplies genetically-defined cell lines, reporter gene assay kits, genomic reference standards and contract research services to organizations engaged in bio-pharmaceutical process optimization, drug discovery & development, and clinical diagnostic development. The company was founded by Christopher John Torrance and Alberto Bardelli on February 14, 2005 and is headquartered in Cambridge, the United Kingdom. | Chief Tech/Sci/R&D Officer | - |
Training of Robert Howes
University of Cambridge | Doctorate Degree |
Experiences
Positions held
Linked companies
Private companies | 2 |
---|---|
Horizon Discovery Ltd.
Horizon Discovery Ltd. Miscellaneous Commercial ServicesCommercial Services Horizon Discovery Ltd. develops and supplying patient-relevant drug discovery and diagnostic research tools. The frm also supplies genetically-defined cell lines, reporter gene assay kits, genomic reference standards and contract research services to organizations engaged in bio-pharmaceutical process optimization, drug discovery & development, and clinical diagnostic development. The company was founded by Christopher John Torrance and Alberto Bardelli on February 14, 2005 and is headquartered in Cambridge, the United Kingdom. | Commercial Services |
Ligand UK Ltd.
Ligand UK Ltd. Pharmaceuticals: MajorHealth Technology Ligand UK Ltd. is a commercial stage pharmaceutical company. Its products include Tuzistra XR, targeting the U.S. prescription cough-cold market, Moxatag, a once-a-day formulation of the antibiotic and amoxicillin, and frovatriptan, used for the acute treatment of migraine. It also develops and commercializes multiple novel products focused on the U.S. prescription cough-cold market. The company was founded by Keith G. McCullagh and Andre L. Lamotte in 1988 and is headquartered in Winnersh, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Robert Howes